Loteprednol etabonate is a site-specific, soft corticosteroid (C-20 ester corticosteroid) designed for topical ophthalmic use. It is a prodrug that undergoes rapid hydrolysis to an inactive metabolite after exerting its anti-inflammatory effect, minimizing systemic absorption and side effects. The 0.2% w/v concentration is primarily indicated for the short-term treatment of post-operative inflammation following ocular surgery.
Adult: 1 drop instilled into the conjunctival sac of the affected eye(s) 4 times daily. In post-operative inflammation, may start 24 hours after surgery and continue for 2 weeks.
Note: Wash hands before use. Tilt head back, pull down lower eyelid to form a pouch. Instill drop without touching the tip to eye or any surface. Close eye gently for 1-2 minutes, applying gentle pressure to the nasolacrimal duct (inner corner of eye) to minimize systemic absorption. Wait at least 5-10 minutes before instilling any other ophthalmic medication.
Loteprednol etabonate binds to glucocorticoid receptors in ocular tissues, leading to the formation of a receptor-ligand complex that translocates to the cell nucleus. This complex binds to glucocorticoid response elements (GREs) on DNA, modulating gene transcription. It inhibits the expression of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), adhesion molecules (ICAM-1), and enzymes like phospholipase A2 and cyclooxygenase-2 (COX-2). This results in reduced synthesis of prostaglandins and leukotrienes, leading to decreased inflammation, edema, fibrin deposition, capillary dilation, and migration of inflammatory cells.
Pregnancy: Category C: Animal studies have shown adverse effects. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus. Systemic absorption is minimal.
Driving: May cause temporary blurred vision. Patients should not drive or operate machinery until vision clears.
| Other Ophthalmic Corticosteroids | Additive risk of elevated IOP, cataract formation, and infection. | Major |
| Ophthalmic NSAIDs (e.g., Ketorolac, Nepafenac) | May increase risk of corneal adverse events (ulceration, perforation) especially post-surgery. Combined use should be under strict supervision. | Major |
| Systemic Corticosteroids (e.g., Prednisone) | Additive systemic corticosteroid effects, though risk is low with topical loteprednol. | Moderate |
| Immunosuppressants | Increased risk of ocular infections. | Moderate |